Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

The Future of Longevity: AI and Nanorobots to Radically Extend Life

by Team Lumida
June 25, 2024
in AI, Health and Longevity
Reading Time: 3 mins read
A A
0
person holding black and white microscope

Photo by Jaron Nix on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. AI-driven drug discovery could drastically cut down clinical trial times.
  2. Medical nanorobots may revolutionize immune systems by the 2030s.
  3. By 2040s, mind-backup systems might allow near-immortality.

What Happened?

Futurist Ray Kurzweil claims that AI will revolutionize drug discovery and medical interventions by the end of the 2020s. He believes biological simulators will soon generate crucial safety and efficacy data in hours, not years.

This shift could lead to faster drug approvals and save countless lives. Kurzweil also predicts that medical nanorobots will emerge in the 2030s, vastly enhancing our immune systems and treating metabolic diseases. By 2040s, he envisions mind-backup systems that could essentially render death obsolete.

Why It Matters?

These advancements could disrupt traditional medical models and extend human lifespans dramatically. Faster drug approvals would mean quicker access to lifesaving treatments. Medical nanorobots could address diseases that our natural immune systems can’t, such as cancer and neurodegenerative disorders.

The potential to back up our minds might lead to radical life extension, fundamentally changing the concept of mortality. Investors should note the profound implications for the healthcare and biotech sectors, which could experience exponential growth.

What’s Next?

Expect increased investment in AI-driven pharmaceutical research and biotech firms focused on nanotechnology. Regulatory landscapes will evolve to accommodate simulated trials, despite potential bureaucratic resistance. By the mid-2040s, mind-backup technologies will likely face ethical and security challenges, but Kurzweil is optimistic about overcoming these hurdles.

As these technologies become mainstream, they will likely follow the trajectory of the cell phone—starting expensive and exclusive, but eventually becoming widely accessible.

Source: Fortune Well
Tags: AI-driven drug discoverymedical nanorobotsmind-backup systemsRay Kurzweil
Previous Post

Bitcoin Crashes to $62K: What’s Behind the $150M Liquidation?

Next Post

TikTok Ban Could Dent Oracle’s Earnings: What Investors Need to Know

Recommended For You

Trump Says the US Could Let Nvidia Sell Blackwell Chips to China in ‘Two Years or Three Years,’ Calling the H200 ‘Semi-Obsolete’ as Congress Moves to Bar Sales for 18 Months

by Team Lumida
1 day ago

Trump said Nvidia could sell Blackwell chips to China in two or three years, as senators push the AI Overwatch Act to bar such sales for at least...

Read more

Intel Signs Its First Outside Customer for 18A Chips and Names Microsoft as Its First Public Customer for EMIB Packaging, After Losing More Than Half Its Value Since September

by Team Lumida
1 day ago
Intel Surges 5%, SK Hynix Up 3% on Reports of U.S. Memory Chip Manufacturing Deal to Serve Nvidia and AI Demand

Intel CEO Lip-Bu Tan said the company signed its first outside customer for 18A chips and named Microsoft as its first public EMIB packaging customer.

Read more

Hims & Hers Launches Five Compounded Peptide and Longevity Treatments on Its Peptides+ Platform After More Than 10,000 Sign Up in 15 Days

by Team Lumida
2 days ago

Hims & Hers began offering five compounded peptide and longevity treatments after HHS eased rules, while admitting there is more to learn on efficacy.

Read more

China’s Military Is ‘Actively Soliciting’ Nvidia’s Most Advanced Chips for AI-Enabled Military Capabilities, a Congressional Commission Says in Its 2026 Report

by Team Lumida
2 days ago

A congressional commission said China’s military is seeking advanced Nvidia chips and evading export controls, including via data centers in Malaysia.

Read more

Bipartisan Push to Attach AI Chip Export Limits to the December NDAA Gains Steam After the Huang Affair, With Schumer, Jeffries and Speaker Johnson Backing the AI Overwatch, MATCH and Chip Security Acts

by Team Lumida
2 days ago

Lawmakers from both parties are pushing three chip export bills into the December defense bill after Jensen Huang’s resignation, but time is short.

Read more

Banks Pause a $480 Million Nvidia GPU Loan to Aolani Cloud Tied to ByteDance After New US Licensing Rules for Malaysia and Singapore Data Centers

by Team Lumida
3 days ago
ByteDance Is Buying Custom Chips From Taiwan Because It Cannot Buy Nvidia’s, Which US Rules Permit

Banks paused or reconsidered a $480 million Aolani Cloud loan for Nvidia GPUs tied to ByteDance after new US licensing rules, Bloomberg reported.

Read more

Commerce and Justice Say They Began Investigating Nvidia Partner Megaspeed in 2024, as Critics Ask Why It Kept Getting Chips After Nvidia’s ‘No Sell’ Listing

by Team Lumida
3 days ago

Commerce and Justice said they opened export-control probes into Megaspeed in 2024 and inspected it in June 2025, as critics question how it kept buying chips.

Read more

Nvidia Warns Chip Buyers That the Remote Access Security Act Could Expose Them to US ‘Legal Action’ and Caps Sales to Clouds Renting Over 50% of GPUs to Chinese Firms

by Team Lumida
3 days ago

Nvidia cautioned customers that the proposed Remote Access Security Act could bring US legal action over Chinese cloud access to its chips, CNBC reported.

Read more

Anthropic’s IPO Could Hand 300-Plus Investors a Windfall, With a $1.33 Trillion Valuation About 38% Above Its $965 Billion May Round

by Team Lumida
4 days ago

Anthropic’s IPO, expected to value it at $1.33 trillion or more, is set to reward over 300 investors, from Spark and Menlo to Amazon and Alphabet.

Read more

Commerce Moves to Close the Offshore Data-Center Loophole for Chinese AI Firms and Requires Licenses for Chip Exports to Five Countries, Its First Policy Response to the Nvidia Scandal

by Team Lumida
4 days ago

Commerce issued a rule curbing Chinese firms’ offshore access to Nvidia compute and requiring chip-export licenses for five higher-risk countries.

Read more
Next Post
a red cube with white text

TikTok Ban Could Dent Oracle's Earnings: What Investors Need to Know

a person holding a phone

AI and Crypto Shakeup: Nvidia and Bitcoin's Massive Drops Explained

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

photo of pub set in room during daytime

TGI Fridays’ Fall from Grace: Iconic Restaurant Chain’s Bankruptcy Marks End of Casual Dining Era

December 27, 2024
a person holding a cell phone with a neon logo on it

TikTok Exits Music-Streaming Market: Key Impacts and Future Moves

September 24, 2024
Intuit Inc. Earnings Highlights

Intuit Inc. Earnings Highlights

August 23, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018